Jack Bikker
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Computational Drug Discovery Methods, Receptor Mechanisms and Signaling, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success(2009)4,214 cited
- → Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies(2009)162 cited
- → G-Protein Coupled Receptors: Models, Mutagenesis, and Drug Design(1998)113 cited
- Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists.(1996)
- → Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates(2017)63 cited
- → Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability(2009)48 cited
- → Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA(2000)48 cited
- → PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers(2020)46 cited
- → Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.(1995)42 cited
- → Direct Oxa-Pictet−Spengler Cyclization to the Natural (3a,5)-trans-Stereochemistry in the Syntheses of (+)-7-Deoxyfrenolicin B and (+)-7-Deoxykalafungin(2008)41 cited